Valeant Pharmaceuticals Agrees to Delay Efinconazole Launch
May 02, 2013 at 20:48 PM EDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) announced that we agreed this afternoon that the launch of efinaconazole, our topical product candidate for the treatment of onychomycosis, will not occur until after the September 2013 arbitration hearing to resolve the breach of contract dispute with Anacor Pharmaceuticals (NASDAQ:
